

Gastrointestinal Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-11-02 | 140 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$2499.00
- Five User Licence \$3499.00
- Enterprisewide License \$4499.00

Report description:

The global gastrointestinal therapeutics market size reached US\$ 44.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 59.6 Billion by 2028, exhibiting a growth rate (CAGR) of 5.1% during 2022-2028.

Gastrointestinal (GI) syndrome refers to a medical ailment that affects the functioning of organs in the digestive tract. It impacts the stomach, pancreas, small and large intestines, gall bladder and liver and is usually characterized by indigestion, heartburn, constipation and bloating. Some of the commonly used GI therapeutics include prescription and over-the-counter (OTC) drugs, such as antacids, laxatives, antidiarrheal agents, antiemetics, antiulcer agents, and endoscopic and radiological procedures and hematological tests. These therapeutics assist in the detection of the disorder and absorbing nutrients from the food to improve digestion, regulate water flow in the GI system and minimize gastric acidity.

The increasing prevalence of GI diseases, such as inflammatory bowel disease (IBD) and ulcerative colitis, is one of the key factors driving the growth of the market. Due to changing lifestyle patterns and unhealthy dietary habits, there is an increased probability of disease recurrence among patients across the globe. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Various technological advancements, such as the development of innovative biosimilars and cellular therapies for the treatment of the disorder, are acting as other growth-inducing factors. These biologics are administered through intravenous and subcutaneous injections and are personalized for targeted treatments. Other factors, including rising health consciousness among the masses, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, especially in developing economies, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global gastrointestinal therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, route of administration, application and distribution channel.

Scotts International. EU Vat number: PL 6772247784

Breakup by Route of Administration
Oral Intravenous Others
Breakup by Application:
Ulcerative Colitis Crohn's Disease GERD Others
Breakup by Distribution Channel:
Hospital Pharmacies Retail Pharmacies Online Pharmacies
Breakup by Region:
North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America

Breakup by Type:

Branded Generic

Scotts International. EU Vat number: PL 6772247784

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, GlaxoSmithKline Plc, Janssen Biotech Inc. (Johnson & Johnson), Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceuticals.

Key Questions Answered in This Report:

How has the global gastrointestinal therapeutics market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global gastrointestinal therapeutics market?

What are the key regional markets?

What is the breakup of the market based on the type?

What is the breakup of the market based on the route of administration?

What is the breakup of the market based on the application?

What is the breakup of the market based on the distribution channel?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the global gastrointestinal therapeutics market and who are the key players?

What is the degree of competition in the industry?

Table of Contents:

- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Gastrointestinal Therapeutics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Type
- 6.1 Branded
- 6.1.1 Market Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

Page 3/9

- 6.1.2 Market Forecast
- 6.2 Generic
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 7 Market Breakup by Route of Administration
- 7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Intravenous
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 8 Market Breakup by Application
- 8.1 Ulcerative Colitis
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Crohn's Disease
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 GERD
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 9 Market Breakup by Distribution Channel
- 9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China

- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico

- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
- 11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
- 12 Value Chain Analysis
- 13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
- 14 Price Analysis
- 15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 AbbVie Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 AstraZeneca Plc
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Bausch Health Companies Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials

- 15.3.4.4 SWOT Analysis
- 15.3.5 Bayer Aktiengesellschaft
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 GlaxoSmithKline Plc
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Janssen Biotech Inc. (Johnson & Johnson)
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Novo Nordisk A/S
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Pfizer Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Takeda Pharmaceuticals
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis



Gastrointestinal Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-11-02 | 140 pages | IMARC Group

To place an Order	with Scotts International:	
☐ - Print this form	n	
☐ - Complete the	e relevant blank fields and sign	
☐ - Send as a sca	anned email to support@scotts-international.com	
ORDER FORM:		
Select license	License	Price
	Electronic (PDF) Single User	\$2499.00
	Five User Licence	\$3499.00
	Enterprisewide License	\$4499.00
	VA	Т
	Tota	ıl
	levant license option. For any questions please contact support@scotts-international.com or 0048 603 d at 23% for Polish based companies, individuals and EU based companies who are unable to provide a	
** VAT will be adde	d at 23% for Polish based companies, individuals and EU based companies who are unable to provide	
** VAT will be adde	d at 23% for Polish based companies, individuals and EU based companies who are unable to provide a	
** VAT will be adde	d at 23% for Polish based companies, individuals and EU based companies who are unable to provide a	
** VAT will be added Email* First Name* Job title*	at 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone* Last Name*	
Email* First Name* Job title* Company Name*	A at 23% for Polish based companies, individuals and EU based companies who are unable to provide a second p	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature

L	